Moreover, it consistently inhibits gallbladder cancer cell growth in vivo in a dose-dependent manner, underscoring the potential of MGCD-265, an MST1R inhibitor, to evolve into a potent anti-gallbladder cancer drug. Here, MST1R is linked to gallbladder cancer.